MX2015016418A - Dihidroetorfina para proporcionar el alivio del dolor y la anestesia. - Google Patents

Dihidroetorfina para proporcionar el alivio del dolor y la anestesia.

Info

Publication number
MX2015016418A
MX2015016418A MX2015016418A MX2015016418A MX2015016418A MX 2015016418 A MX2015016418 A MX 2015016418A MX 2015016418 A MX2015016418 A MX 2015016418A MX 2015016418 A MX2015016418 A MX 2015016418A MX 2015016418 A MX2015016418 A MX 2015016418A
Authority
MX
Mexico
Prior art keywords
dihydroetorphine
pain relief
anaesthesia
provision
subject
Prior art date
Application number
MX2015016418A
Other languages
English (en)
Spanish (es)
Inventor
Smith Kevin
Watkins David
Oksche Alexander
Mansikka Heikki
Bailey Paul
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of MX2015016418A publication Critical patent/MX2015016418A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2015016418A 2013-05-30 2014-05-30 Dihidroetorfina para proporcionar el alivio del dolor y la anestesia. MX2015016418A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1309654.0A GB201309654D0 (en) 2013-05-30 2013-05-30 Method
PCT/GB2014/000206 WO2014191710A1 (en) 2013-05-30 2014-05-30 Dihydroetorphine for the provision of pain relief and anaesthesia

Publications (1)

Publication Number Publication Date
MX2015016418A true MX2015016418A (es) 2016-11-08

Family

ID=48805475

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016418A MX2015016418A (es) 2013-05-30 2014-05-30 Dihidroetorfina para proporcionar el alivio del dolor y la anestesia.

Country Status (13)

Country Link
US (2) US10898479B2 (enExample)
EP (1) EP3003310A1 (enExample)
JP (3) JP2016520114A (enExample)
KR (1) KR20160013977A (enExample)
CN (1) CN105555274A (enExample)
AU (1) AU2014272924B2 (enExample)
BR (1) BR112015029709A2 (enExample)
CA (1) CA2913849A1 (enExample)
GB (1) GB201309654D0 (enExample)
HK (1) HK1222585A1 (enExample)
MX (1) MX2015016418A (enExample)
PH (1) PH12015502655A1 (enExample)
WO (1) WO2014191710A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX369121B (es) 2011-03-04 2019-10-30 Gruenenthal Gmbh Formulacion farmaceutica acuosa de tapentadol para administracion oral.
EA036258B1 (ru) 2015-03-27 2020-10-20 Грюненталь Гмбх Стабильный препарат для парентерального введения тапентадола
GB201513442D0 (en) * 2015-07-30 2015-09-16 Euro Celtique Sa Transdermal patch
CN109996533A (zh) 2016-09-23 2019-07-09 格吕伦塔尔有限公司 用于肠胃外施用他喷他多的稳定制剂
EP3585370A1 (en) 2017-02-23 2020-01-01 Grünenthal GmbH Tapentadol as local anesthetic

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB937214A (en) 1961-06-02 1963-09-18 J F Macfarlan & Company Ltd Oripavine derivatives
GB925723A (en) 1960-09-05 1963-05-08 J F Macfarlan & Company Ltd Novel thebaine derivatives
JPS59184182A (ja) 1983-04-02 1984-10-19 Res Inst For Prod Dev ３−ベンゾイルチオ−４、５α−エポキシ−７α−〔１（Ｒ）−ヒドロキシ−１−メチルベンチル〕−６−メトキシ−１７−メチル−６、１４−エンド−エタノモルヒナン
JPS62153214A (ja) 1985-12-26 1987-07-08 Nitto Electric Ind Co Ltd 医薬製剤
JPS62281815A (ja) 1986-05-27 1987-12-07 Teisan Seiyaku Kk 貼付剤及びその製造法
JPS63201119A (ja) 1987-02-17 1988-08-19 Kao Corp 貼付剤組成物
US4891377A (en) 1988-12-02 1990-01-02 Board Of Regents Acting For And On Behalf Of University Of Michigan Transdermal delivery of the narcotic analgesics etorphine and analogs
PT95069B (pt) 1989-08-24 1997-10-31 Searle & Co Processo para a preparacao de (+)-isomeros de derivados de endoetano/endoetanoepoximofinano, uteis como agentes anti-tussicos
US5271940A (en) 1989-09-14 1993-12-21 Cygnus Therapeutic Systems Transdermal delivery device having delayed onset
US5633259A (en) 1992-09-21 1997-05-27 United Biomedical, Inc. Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction
EP0668764A1 (en) 1992-09-21 1995-08-30 QIN, Bo-yi Methods for identifying and using low/non-addictive opioid analgesics
JP2819236B2 (ja) 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
HU228434B1 (en) 1995-06-07 2013-03-28 Ortho Mcneil Pharm Inc Transdermal medicament for administering 17-deacetyl norgestimate alone or in combination with an estrogen
AUPN603895A0 (en) 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
US6103258A (en) 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
KR100204659B1 (ko) 1996-05-28 1999-06-15 강재헌 신규한 부프레노핀계 진통제용 화합물
JPH10231248A (ja) 1997-02-19 1998-09-02 T T S Gijutsu Kenkyusho:Kk ジヒドロエトルフィン含有経皮吸収型製剤
CA2311755C (en) 1998-08-27 2010-03-23 Pharmacia & Upjohn Ab Therapeutic formulation for administering tolterodine with controlled release
US6194382B1 (en) 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US6765010B2 (en) 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
US6312716B1 (en) 1999-05-10 2001-11-06 Peierce Management Llc Patch and method for transdermal delivery of bupropion base
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP4659943B2 (ja) 2000-02-25 2011-03-30 帝三製薬株式会社 塩酸ブプレノルフィン含有貼付剤
CN1438861A (zh) 2000-04-26 2003-08-27 沃特森药物公司 最小化与奥昔布宁疗法有关的副作用
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
AU782523B2 (en) 2000-07-13 2005-08-04 Euro-Celtique S.A. Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
EP1423392B1 (en) 2001-08-10 2006-10-04 Neuro Therapeutics Limited Derivatives of morphine-like opioid compounds
CN1233645C (zh) 2001-09-14 2005-12-28 中国人民解放军军事医学科学院毒物药物研究所 新的东罂粟碱衍生物及其医药用途
AU2003219680A1 (en) 2002-01-23 2003-09-02 The Regents Of The University Of California Methods and compositions for reducing the development of drug tolerance and/or physical dependence
US20060177381A1 (en) 2002-02-15 2006-08-10 Howard Brooks-Korn Opiopathies
US20040033253A1 (en) 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
US20060039960A1 (en) 2002-05-28 2006-02-23 Cordes Guenter Plaster containing fentanyl
NZ537180A (en) 2002-06-10 2008-03-28 Euro Celtique Sa Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein
WO2004017941A2 (en) 2002-08-20 2004-03-04 Euro-Celtique, S.A. Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
AU2002951965A0 (en) 2002-10-09 2002-10-24 Monash University Amidine compounds
TWI296531B (en) 2002-10-18 2008-05-11 Hisamitsu Pharmaceutical Co Transdermal adhesive preparations for topical administration of fentanyl
TW200500067A (en) 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
US20040208917A1 (en) 2003-04-16 2004-10-21 Wilfried Fischer Transdermal systems for the release of clonidine
AU2004235794B8 (en) 2003-04-30 2009-07-23 Purdue Pharma L.P. Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
US20050113365A1 (en) 2003-11-10 2005-05-26 Sir Isaac Newton Enterprises Llc Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome
CN100500151C (zh) 2004-04-02 2009-06-17 北京万全阳光医药科技有限公司 一种水溶性药物舌下给药制剂
JP2007538091A (ja) 2004-05-17 2007-12-27 ファーマコフォア・インコーポレイテッド 痛みを処置または予防するための組成物および方法
CA2604887A1 (en) 2005-04-07 2006-10-19 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
WO2007004067A2 (en) 2005-04-15 2007-01-11 Interface Biologics Inc. Methods and compositions for the delivery of biologically active agents
KR100764679B1 (ko) 2005-07-22 2007-10-09 익수제약 주식회사 파록세틴을 함유하는 경피투여용 패취제
EP1928881A2 (en) 2005-08-19 2008-06-11 Pharmacofore, Inc. Prodrugs of active agents
WO2007052308A2 (en) 2005-11-03 2007-05-10 Brain N' Beyond Biotech Pvt. Ltd. Glyco-phosphorylated biologically active agents
GB0523031D0 (en) 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
WO2007065303A1 (en) 2005-12-09 2007-06-14 Beijing Kangbeide Pharmaceutical Technology Development Co., Ltd. Transdermal patch containing isosorbide dinitrate and bisoprolol
AU2007225056A1 (en) 2006-03-15 2007-09-20 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
USD576282S1 (en) 2006-06-16 2008-09-02 Activatek, Inc. Adhesive transdermal medicament patch
USD625017S1 (en) 2006-08-11 2010-10-05 Hisamitsu Pharmaceutical Co., Inc. Medical transdermal patch
DE102006050558B4 (de) 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
CN100512817C (zh) 2006-11-15 2009-07-15 闫章年 复方噻拉嗪注射液及制备工艺
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
US20100158990A1 (en) 2006-12-27 2010-06-24 Abielle Pharmaceuticals, Inc Transdermal method and patch for corticosteroid administration
PL2137189T3 (pl) 2007-03-06 2015-12-31 SpecGx LLC Sposób wytwarzania czwartorzędowych N-alkilowych soli alkaloidu morfinanowego
CN101147739B (zh) 2007-07-06 2010-12-08 北京康倍得医药技术开发有限公司 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
KR100929560B1 (ko) 2008-01-09 2009-12-03 에코 퍼시픽 엘티디 그라니세트론을 함유한 매트릭스 형태의 경피 흡수제
JP5547065B2 (ja) 2008-05-15 2014-07-09 久光製薬株式会社 パロノセトロンを含有する経皮吸収製剤
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
EP2298277A1 (en) 2009-09-09 2011-03-23 Labtec GmbH Transdermal patch formulation
DE102010040299A1 (de) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)

Also Published As

Publication number Publication date
KR20160013977A (ko) 2016-02-05
AU2014272924A1 (en) 2016-01-28
WO2014191710A1 (en) 2014-12-04
CN105555274A (zh) 2016-05-04
US10898479B2 (en) 2021-01-26
BR112015029709A2 (pt) 2017-07-25
US20160106736A1 (en) 2016-04-21
JP2019123730A (ja) 2019-07-25
AU2014272924B2 (en) 2019-05-02
JP2020200345A (ja) 2020-12-17
JP2016520114A (ja) 2016-07-11
HK1222585A1 (zh) 2017-07-07
PH12015502655A1 (en) 2016-03-07
EP3003310A1 (en) 2016-04-13
GB201309654D0 (en) 2013-07-17
CA2913849A1 (en) 2014-12-04
US20210085673A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
IN2015DN03219A (enExample)
PH12016500619A1 (en) Dry powder inhaler
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX378263B (es) Terapia de combinación para el tratamiento del cáncer.
PH12014502058A1 (en) Pharmaceutical composition comprising empagliflozin and antiobesity drug
MY173215A (en) Acetylcysteine compositions and methods of use thereof
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
MX2021005317A (es) Composiciones y métodos para absorción transmucosa.
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
UA98136C2 (ru) Применение аклидиния для лечения респираторных заболеваний
EP4378524A3 (en) Treatment of fabry disease in ert-naive and ert-experienced patients
MX2015012322A (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MY204827A (en) Semaglutide in medical therapy
MX2015016418A (es) Dihidroetorfina para proporcionar el alivio del dolor y la anestesia.
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
MX382776B (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
WO2013181217A3 (en) Novel compounds and compositions for treatment of breathing control disorders or diseases